Stem Cell Transplantation

1. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

Author
Chang C; Storer BE; Scott BL; Bryant EM; Shulman HM; Flowers ME; Sandmaier BM; Witherspoon RP; Nash RA; Sanders JE; Bedalov A; Hansen JA; Clurman BE; Storb R; Appelbaum FR; Deeg HJ; Chang C; Storer BE; Scott BL; Bryant EM; Shulman HM; Flowers ME; Sandmaier BM; Witherspoon RP; Nash RA; Sanders JE; Bedalov A; Hansen JA; Clurman BE; Storb R; Appelbaum FR; Deeg HJ; Chang C; Storer BE; Scott BL; Bryant EM; Shulman HM; Flowers ME; Sandmaier BM; Witherspoon RP; Nash RA; Sanders JE; Bedalov A; Hansen JA; Clurman BE; Storb R; Appelbaum FR; Deeg HJ;
Institution
Department of Hematology, Shanghai Sixth People's Hospital, Shanghai JiaoTong University, Shanghai, People's Republic of China.
Journal
Blood. 2007 Aug 15;110(4):1379-87. Epub 2007 May 8.
Abstract URL
Click here to view abstract

2. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

Author
Armand P; Kim HT; DeAngelo DJ; Ho VT; Cutler CS; Stone RM; Ritz J; Alyea EP; Antin JH; Soiffer RJ;
Institution
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Journal
Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64. Epub 2007 Mar 21.
Abstract URL
Click here to view abstract

3. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.

Author
Scott BL; Storer BE; Greene JE; Hackman RC; Appelbaum FR; Deeg HJ;
Institution
Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. bscott@fhcrc.org <bscott@fhcrc.org>
Journal
Biol Blood Marrow Transplant. 2007 Mar;13(3):345-54.
Abstract URL
Click here to view abstract

4. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Author
Al-Ali HK; Brand R; van Biezen A; Finke J; Boogaerts M; Fauser AA; Egeler M; Cahn JY; Arnold R; Biersack H; Niederwieser D; de Witte T;
Institution
Department of Hematology/Oncology, University of Leipzig, Leipzig, Germany. alah@medizin.uni-leipzig.de
Journal
Leukemia. 2007 Sep;21(9):1945-51. Epub 2007 Jul 5.
Abstract URL
Click here to view abstract

5. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis.

Author
Flynn CM; Hirsch B; Defor T; Barker JN; Miller JS; Wagner JE; Blazar BR; Burns LJ; Macmillan ML; Arora M; Weisdorf D;
Institution
Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
Journal
Am J Hematol. 2007 Oct;82(10):867-72.
Abstract URL
Click here to view abstract

6. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

Author
Armand P; Kim HT; Cutler CS; Ho VT; Koreth J; Ritz J; Alyea EP; Antin JH; Soiffer RJ;
Institution
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. parmand@partners.org
Journal
Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35. Epub 2007 Nov 26.
Abstract URL
Click here to view abstract

7. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Author
Castro-Malaspina H; Jabubowski AA; Papadopoulos EB; Boulad F; Young JW; Kernan NA; Perales MA; Small TN; Hsu K; Chiu M; Heller G; Collins NH; Jhanwar SC; van den Brink M; Nimer SD; O'Reilly RJ;
Institution
The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. castro-h@mskcc.org
Journal
Biol Blood Marrow Transplant. 2008 Apr;14(4):458-68.
Abstract URL
Click here to view abstract

8. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.

Author
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR;
Institution
Division of Hematology/Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. rnakamura@coh.org
Journal
Bone Marrow Transplant. 2007 Nov;40(9):843-50. Epub 2007 Aug 27.
Abstract URL
Click here to view abstract

9. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.

Author
Campregher PV; Gooley T; Scott BL; Moravec C; Sandmaier B; Martin PJ; Deeg HJ; Warren EH; Flowers ME;
Institution
Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109, USA.
Journal
Bone Marrow Transplant. 2007 Nov;40(10):965-71. Epub 2007 Sep 10.
Abstract URL
Click here to view abstract

10. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Author
Ducastelle S; Ades L; Gardin C; Dombret H; Prebet T; Deconinck E; Rio B; Thomas X; Debotton S; Guerci A; Gratecos N; Stamatoullas A; Fegueux N; Dreyfus F; Fenaux P; Wattel E;
Institution
Service d'Hematologie, Pavillon E, CHU, Hopital Edouard Herriot, 5, place d'Arsonval, 69437 Lyon Cedex 03, France.
Journal
Haematologica. 2006 Mar;91(3):373-6.
Abstract URL
Click here to view abstract

11. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.

Author
de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
Institution
Dept. of Hematology, Radboud University Medical Center Nijmegen, The Netherlands.
Journal
Haematologica. 2006 Jun;91(6):750-6.
Abstract URL
Click here to view abstract

12. Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders.

Author
Scott B; Deeg HJ;
Institution
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1-100, P.O. Box 19024, Seattle, WA 98109-1024, USA.
Journal
Best Pract Res Clin Haematol. 2006;19(3):519-33.
Abstract URL
Click here to view abstract

13. Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome.

Author
Tamura K; Kanazawa T; Suzuki M; Koitabashi M; Ogawa C; Morikawa A;
Institution
Department of Pediatrics and Developmental Medicine, Gunma University Graduate School, Maebashi, Japan. ktamura@med.gunma-u.ac.jp
Journal
Am J Hematol. 2006 Feb;81(2):139-41.
Abstract URL
Click here to view abstract

14. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.

Author
Scott BL; Sandmaier BM; Storer B; Maris MB; Sorror ML; Maloney DG; Chauncey TR; Storb R; Deeg HJ;
Institution
Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
Journal
Leukemia. 2006 Jan;20(1):128-35.
Abstract URL
Click here to view abstract

15. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.

Author
Kroger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Institution
Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany. nkroeger@uke.uni-hamburg.de
Journal
Bone Marrow Transplant. 2006 Jan;37(2):183-9.
Abstract URL
Click here to view abstract

16. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.

Author
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR; Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR;
Institution
Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis, Missouri, USA.
Journal
Biol Blood Marrow Transplant. 2006 Jul;12(7):749-57.
Abstract URL
Click here to view abstract

17. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.

Author
Armand P; Kim HT; Cutler CS; Ho VT; Koreth J; Alyea EP; Soiffer RJ; Antin JH;
Institution
Journal
Blood. 2007 May 15;109(10):4586-8. Epub 2007 Jan 18.
Abstract URL
Click here to view abstract

18. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.

Author
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S;
Institution
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. tmori@sc.itc.keio.ac.jp
Journal
Bone Marrow Transplant. 2007 Feb;39(4):217-21. Epub 2007 Jan 15.
Abstract URL
Click here to view abstract